Mid and South Essex NHS Foundation Trust - Basildon University Hospital

The Mid and South Essex NHS Foundation Trust - Basildon University Hospital incorporates Basildon University Hospital https://www.mse.nhs.uk//
Chemotherapy toxicity data presented at trust level because 86% of data was coded at trust level.

View Trust Services

This trust offers the following services:

  • Diagnostic and pre-operative services:
    • On-site PET-CT facilities
    • On-site Cardio-Pulmonary Exercise Testing (CPET) facilities
    • Routine Genetic Testing for Lynch Syndrome
  • Surgical services:
    • On-site thoracic surgical team
    • Robotic surgery
  • Advanced disease services:
    • Dedicated Specialist Advanced MDT
    • Extended lymphadenectomy
  • Support service facilities:
    • Dedicated nurses for ERAS services

Data Quality
All Patients: Trust Network National
Number of patients in Audit 232 1867 35779
Case ascertainment (%) Good Good Good
Data completeness of:
– Pre-treatment TNM (%) 78 85 86
– Performance status (%) 100 96 89
Patients having major resection: Trust Network National
Number of patients in Audit 150 1016 19631
ASA grade 1 (%) 5 11 9
ASA grade 2 (%) 48 50 53
ASA grade 3 (%) 45 36 31
ASA grade 4+ (%) 3 3 2
ASA grade not recorded (%) N/A 1 4
Data completeness of:
7 Audit items for risk-adjustment (%) 99 93 87

Key:

> 80%
50 - 80%
< 50%

Management of all patients
All Patients: Trust Network National
Number of patients in Audit 232 1867 35779
Seen by Clinical Nurse Specialist (%) 98 94 88

Management of patients having major resection
Patients having major resection: Trust Network National
Number of patients in Audit 150 1016 19614
Distant metastases (%) 1 5 5
Urgent or emergency surgery (%) 7 11 15
At least 12 lymph nodes excised (%) 100 89 84
Laparoscopic surgery attempted (%) 94 80 72
Risk-adjusted length of stay > 5 days (%) 51 46 55
Patients having major resection for stage III colon cancer: Trust Network National
Number of patients in audit 70 N/A 10747
Adjuvant chemotherapy (%) 54 N/A 62
Patients receiving chemotherapy after major resection for stage III colon cancer: Trust Network National
Number of patients in audit 95 N/A 6608
Severe acute toxicity after adjuvant chemotherapy (%) 30 N/A 22

Rectal cancer patients
Patients having major resection: Trust Network National
Number of patients in Audit 33 N/A 4251
Neoadjuvant therapy (%) 12 N/A 33
Circumferential resection margin: Recorded (%) 100 94 89
Circumferential resection margin: Negative (%) 97 90 83
Rectal volume 36 N/A 4377
Patients in APER/Hartmanns estimate: Trust Network National
Number of patients in APER/Hartmanns estimate 128 936 19644
APER/Hartmanns (%) 23 34 37

Compare trust outcomes

Copyright © 2024 National Bowel Cancer Audit | Lovingly Crafted by Mixd